Jefferies Financial Group Comments on Esperion Therapeutics Inc’s Q4 2020 Earnings (NASDAQ:ESPR)
Esperion Therapeutics Inc (NASDAQ:ESPR) – Investment analysts at Jefferies Financial Group cut their Q4 2020 EPS estimates for shares of Esperion Therapeutics in a research report issued on Wednesday, November 6th. Jefferies Financial Group analyst M. Yee now anticipates that the biopharmaceutical company will earn $2.54 per share for the quarter, down from their prior estimate of $2.67.
Other analysts have also recently issued research reports about the stock. Northland Securities restated a “buy” rating on shares of Esperion Therapeutics in a research report on Thursday, August 29th. Cowen restated a “buy” rating on shares of Esperion Therapeutics in a research report on Wednesday. Goldman Sachs Group upgraded shares of Esperion Therapeutics from a “sell” rating to a “neutral” rating and lowered their price objective for the company from $55.00 to $45.00 in a research report on Monday, September 16th. ValuEngine upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. Finally, Stifel Nicolaus lowered their price objective on shares of Esperion Therapeutics from $112.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Esperion Therapeutics has a consensus rating of “Buy” and an average target price of $70.44.
Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($2.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.95) by ($0.42). The firm had revenue of $0.98 million for the quarter, compared to analysts’ expectations of $0.99 million. During the same quarter in the prior year, the business posted ($1.86) EPS.
In other Esperion Therapeutics news, CEO Timothy M. Mayleben bought 5,000 shares of Esperion Therapeutics stock in a transaction that occurred on Wednesday, September 4th. The shares were bought at an average price of $34.20 per share, with a total value of $171,000.00. Following the acquisition, the chief executive officer now owns 76,015 shares in the company, valued at $2,599,713. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Target N. V. Biotech purchased 75,000 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was purchased at an average cost of $37.30 per share, for a total transaction of $2,797,500.00. Following the acquisition, the insider now owns 3,727,964 shares in the company, valued at $139,053,057.20. The disclosure for this purchase can be found here. In the last ninety days, insiders have purchased 167,500 shares of company stock worth $5,943,925. 7.70% of the stock is owned by insiders.
Institutional investors have recently made changes to their positions in the business. Aperio Group LLC bought a new stake in Esperion Therapeutics in the 2nd quarter worth $29,000. Russell Investments Group Ltd. bought a new stake in Esperion Therapeutics in the 2nd quarter worth $32,000. Tower Research Capital LLC TRC bought a new stake in Esperion Therapeutics in the 3rd quarter worth $42,000. Bank of Montreal Can grew its holdings in Esperion Therapeutics by 364.5% in the 2nd quarter. Bank of Montreal Can now owns 2,671 shares of the biopharmaceutical company’s stock worth $125,000 after acquiring an additional 2,096 shares during the last quarter. Finally, Royal Bank of Canada grew its holdings in Esperion Therapeutics by 38.1% in the 2nd quarter. Royal Bank of Canada now owns 2,938 shares of the biopharmaceutical company’s stock worth $137,000 after acquiring an additional 811 shares during the last quarter.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.